Effect and economic comparison among different liver protective drugs in treatment of anti-rheumatoid drug-induced liver injury
Li Rongxia
Liu Jie
Zhao Linglin
Liu Xiang
Yang Chengshuang
Abstract：Objective To analyze the efficacy and cost of different hepatoprotective drugs in treatment of anti-rheumatoid drug-induced liver injury.Methods A total of 159 patients with liver injury caused by anti-rheumatoid drugs admitted to Qinghai Provincial People's Hospital from October 2015 to October 2017 were randomly divided into group A,group B and group C,with 53 patients in each group.Group A was treated with reduced glutathione;group B was treated with magnesium isoglycyrrhizinate;group C was treated with hepatocyte growth-promoting factor.After 2 weeks of treatment,clinical efficacy,liver function [alanine aminotransferase (ALT),aspartate aminotransferase(AST),total bilirubin (TBIL) and glutamyltranspetidase (GGT)],adverse reactions and drug cost were analyzed.Results Total effective rate showed no significant difference among the three groups (P ＞ 0.05).Before treatment,there was no significant difference of serum liver function indexes among groups (P ＞ 0.05).After treatment,levels of serum ALT,AST,TBIL and GGT significantly decreased and the levels in group B were significantly lower than those in group A and group C [(42 ± 5) U/L vs (66 ± 6),(64 ± 7) U/L;(56±7)U/Lvs (79 ±8),(81 ±8)U/L;(16.1 ±2.0)μmol/L vs (20.4 ±2.4),(19.8±2.5)μmol/L;(141 ± 8) U/L vs (188 ± 10),(190 ± 12) U/L] (all P ＜ 0.05);there was no significant difference between group A and group C (all P ＞ 0.05).There was no significant difference of the incidence of adverse reactions among groups(P ＞ 0.05).Cost of drugs in group B was significantly lower than that in group A and group C [(974 ± 122) yuan vs (1 482 ± 250),(1 305 ± 146) yuan];the cost in group C was significantly lower than that in group A (all P ＜ 0.05).Conclusion Magnesium isoglycyrrhizinate shows better effect on liver function recovery and lower medical cost than reducedglutathione and hepatocyte growth-promoting factor in treatment of anti-rheumatoid drug-induced liver injury and does not increase adverse reactions.
Keywords：Drug-induced liver injuryMagnesium isoglycyrrhizinateReduced glutathioneHepatocyte growth-promoting factorAnti-rheumatoid drug
Publication Date：2019-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 396-399 )